Community-driven development of a modified progression-free survival ratio for precision oncology

OBJECTIVE: Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecularly guided therapy (PFS2) divided by the PFS int...

全面介紹

Na minha lista:
書目詳細資料
發表在:ESMO Open
Main Authors: Mock, Andreas, Heilig, Christoph E, Kreutzfeldt, Simon, Huebschmann, Daniel, Heining, Christoph, Schröck, Evelin, Brors, Benedikt, Stenzinger, Albrecht, Jäger, Dirk, Schlenk, Richard, Glimm, Hanno, Fröhling, Stefan, Horak, Peter
格式: Artigo
語言:Inglês
出版: BMJ Publishing Group 2019
主題:
Original Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6863673/
https://ncbi.nlm.nih.gov/pubmed/31798980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000583
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍